Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model

Abstract

These results indicate that FlaB can be a promising mucosal adjuvant for nasal HPV vaccine development.